

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ

<u>L7</u>	('LFA-3' or LFA3TIP or LFA3\$) and (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$)same (skin or dermatitis or psoriasis)	120	<u>L7</u>
-----------	--	-----	-----------

DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ

<u>L6</u>	('LFA-3' or LFA3TIP or LFA3\$) and (treat\$ or therap\$ or prevent\$ or inhibit\$ or suppress\$)same (skin or dermatitis or psoriasis)	181	<u>L6</u>
-----------	--	-----	-----------

DB=USPT,PGPB; PLUR=YES; OP=ADJ

<u>L5</u>	('LFA-3' or LFA3TIP or LFA3\$) and (skin or dermatitis or psoriasis)	260	<u>L5</u>
-----------	--	-----	-----------

<u>L4</u>	('LFA-3' or LFA3TIP or LFA3\$)same (skin or dermatitis or psoriasis)	12	<u>L4</u>
-----------	--	----	-----------

<u>L3</u>	('LFA-3' or LFA3TIP or LFA3\$) and (psoriasis)	89	<u>L3</u>
-----------	--	----	-----------

<u>L2</u>	L1 and lfa\$	10	<u>L2</u>
-----------	--------------	----	-----------

<u>L1</u>	wallner-barbara\$	21	<u>L1</u>
-----------	-------------------	----	-----------

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
LFA-3.USPT.	361
LFA-3S	0
LFA3TIP.USPT.	10
LFA3TIPS	0
SKIN.USPT.	141764
SKINS.USPT.	9868
DERMATITIS.USPT.	7041
DERMATITI.USPT.	3
PSORIASIS.USPT.	10645
PSORIASI.USPT.	4
LFA3\$	0
((('LFA-3' OR LFA3TIP OR LFA3\$) AND (TREAT\$ OR THERAP\$ OR PREVENT\$ OR INHIBIT\$ OR SUPPRESS\$)SAME (SKIN OR DERMATITIS OR PSORIASIS)).USPT.	120

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L7

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: **Saturday, March 29, 2003** [Printable Copy](#) [Create Case](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 10 of 10 returned.**

-
- ☐ 1. [20020009449](#). 05 Dec 00. 24 Jan 02. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction. [Wallner, Barbara P.](#), et al. 424/154.1; A61K039/395.
-
- ☐ 2. [6162432](#). 06 Jun 95; 19 Dec 00. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction. [Wallner, Barbara P.](#), et al. 424/154.1; 424/130.1 424/133.1 424/134.1 424/135.1 424/141.1 424/143.1 424/144.1 424/152.1 424/153.1 424/172.1 424/173.1 424/185.1 424/192.1 514/15 514/2 514/8 514/863 514/888. A61K039/395 A61K035/26 A61K038/17.
-
- ☐ 3. [5928643](#). 02 Jun 95; 27 Jul 99. Method of using CD2-binding domain of lymphocyte function associated antigen 3 to initiate T cell activation. [Wallner, Barbara P.](#), et al. 424/134.1; 424/153.1 424/173.1 424/182.1 424/185.1 424/192.1 435/69.7 514/12 530/324 530/387.1. A61K039/395 A61K038/16 C12N015/62 C07K014/705.
-
- ☐ 4. [5914111](#). 02 Jun 95; 22 Jun 99. CD2-binding domain of lymphocyte function associated antigen-3. [Wallner, Barbara P.](#), et al. 424/134.1; 424/153.1 424/173.1 424/182.1 424/185.1 424/192.1 435/69.7 514/12 530/324 530/387.1. A61K039/395 A61K038/16 C12N015/62 C07K014/705.
-
- ☐ 5. [5728677](#). 02 Jun 95; 17 Mar 98. Methods of inhibiting T-cell dependent proliferation of peripheral blood lymphocytes using the CD2-binding domain of lymphocyte function associated antigen 3. [Wallner, Barbara P.](#), et al. 514/12; 424/185.1 424/809 514/13 514/15 530/868. A61K038/17 C07K014/705.
-
- ☐ 6. [5547853](#). 21 Oct 92; 20 Aug 96. CD2-binding domain of lymphocyte function associated antigen 3. [Wallner, Barbara P.](#), et al. 435/69.1; 435/252.3 435/320.1 435/69.7 435/810 436/86 514/2 530/350 536/23.4 536/23.5. C07K014/705 C12N015/12 C12N015/62.
-
- ☐ 7. [5354665](#). 13 Oct 92; 11 Oct 94. Recombinant DNA processes for producing PI-linked lymphocyte function associated antigen-3. [Wallner, Barbara P.](#), et al. 435/69.3; 514/2 514/8 530/350 530/387.1 530/395. C07K013/00 A61K037/02 C12N015/10.
-
- ☐ 8. [5223394](#). 10 Apr 89; 29 Jun 93. Recombinant DNA molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence. [Wallner, Barbara P.](#), et al. 435/6; 435/252.3 435/320.1 536/23.5 536/23.53. C12Q001/68 C12N015/00.
-
- ☐ 9. [5185441](#). 26 Aug 88; 09 Feb 93. DNA sequences, recombinant DNA molecules and processes for producing PI-linked lymphocyte function associated antigen-3. [Wallner, Barbara P.](#), et al. 435/356; 435/252.31 435/252.34 435/320.1 435/362 435/6 435/69.3 435/90 436/501 536/23.5. C07H021/00 C07H021/04 C12Q001/68.
-
- ☐ 10. [4956281](#). 03 Jun 87; 11 Sep 90. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3. [Wallner, Barbara P.](#), et al. 435/69.3; 435/252.31 435/252.33 435/252.34 435/252.35 435/254.11 435/254.22 435/320.1 435/356 435/366 536/23.1 536/23.5. C12P021/00 C12N015/00 C12N001/20.
-

[Generate Collection](#)[Print](#)

Term	Documents
LFA\$	0
LFA.USPT,PGPB.	1751
LFAA.USPT,PGPB.	18
LFAAFPSFAG.USPT,PGPB.	1
LFAAISTRQY.USPT,PGPB.	1
LFAAS.USPT,PGPB.	5
LFAA1Z01618H.USPT,PGPB.	1
LFAA1200110H.USPT,PGPB.	1
LFAA12034.USPT,PGPB.	1
LFAA/MFAA.USPT,PGPB.	4
LFAB.USPT,PGPB.	2
(L1 AND LFA\$).USPT,PGPB.	10

[There are more results than shown above. Click here to view the entire set.](#)

[Previous Page](#)[Next Page](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=DWPI; PLUR=YES; OP=ADJ

L5 (puva or uv or chemotherapy) same (combination or combined)same
psoriasis

42

L5*DB=USPT; PLUR=YES; OP=ADJ*

L4 (uv or chemotherapy) same (combination or combined)same psoriasis

80

L4

L3 (uv or chemotherapy) same (combination or combined)and psoriasis

829

L3

L2 L1 and psoriasis

47

L2

L1 (puva) same (combination or combined)

51

L1

END OF SEARCH HISTORY

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)[Cases](#)**Search Results -**

Term	Documents
PUVA.DWPL.	15
PUVAS	0
UV.DWPL.	57602
UVS.DWPL.	8
CHEMOTHERAPY.DWPL.	3405
CHEMOTHERAPIES.DWPL.	20
CHEMOTHERAPYS	0
COMBINATION.DWPL.	232997
COMBINATIONS.DWPL.	22370
COMBINED.DWPL.	167171
COMBINEDS.DWPL.	2
((PUVA OR UV OR CHEMOTHERAPY) SAME (COMBINATION OR COMBINED)SAME PSORIASIS).DWPL.	42

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database	▲
US Pre-Grant Publication Full-Text Database	
JPO Abstracts Database	
EPO Abstracts Database	
Derwent World Patents Index	▼
IBM Technical Disclosure Bulletins	

Search:

L5

[Refine Search](#)[Recall Text](#)[Clear](#)**Search History**

DATE: Saturday, March 29, 2003 [Printable Copy](#) [Create Case](#)

☐ Generate Collection

L4: Entry 72 of 80

File: USPT

Apr 1, 1986

DOCUMENT-IDENTIFIER: US 4579844 A

TITLE: Topical anti-inflammatory drug therapy

Brief Summary Text (7):

We have discovered in the course of investigations with experimentally induced inflammation that topical treatment with a combination of certain steroidal and non-steroidal anti-inflammatory drugs results in unexpectedly improved suppression of inflammation than occurs when either drug is used alone. That is, either the combination is effective where the drugs used separately are not, or the combination provides more rapid, dramatic improvement than either drug alone, or the combination is equally effective at lower concentrations than either drug alone. This effect is postulated to result from the two drugs acting upon different aspects of the inflammatory response. Particularly in the case of UV-induced erythema, significant therapeutic effects (amelioration of the condition) are produced by combinations of the two types of drugs at concentration levels at which either drug alone has low or minimal effect. The steroid/non-steroid drug combination treatment of the present invention can also be used in the therapeutic treatment of a wide variety of dermatological disorders in which inflammation is a component. Examples of these diseases are psoriasis, eczema, contact dermatitis, atopic dermatitis, etc. Inflammation accompanying thermal or chemical burns as well as sunburn are other areas for application of the combination therapy of this invention, as are diaper rash, insect bite inflammation, gingival inflammation and pruritus. Also, vesicular diseases, especially those characterized by acantholysis, and other blistering conditions, appear to be particularly susceptible to this therapy.